# Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery

Study · id `cardio:ct-nct03900026` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03900026](<https://clinicaltrials.gov/study/NCT03900026>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03900026

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 782 participants.

## Technical summary

Registry record NCT03900026. Randomized; quadruple masking; primary purpose prevention. Start 2019-05-30 (actual); primary completion 2025-01-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 782 participants (enrolled count; ClinicalTrials.gov record NCT03900026, source copy `cardio:ctgov-nct03900026-2025-08-29`, retrieved 2026-10-31)
- Started: 2019-05-30 (actual) (ClinicalTrials.gov record NCT03900026, source copy `cardio:ctgov-nct03900026-2025-08-29`, retrieved 2026-10-31)
- Primary completion: 2025-01-30 (actual) (ClinicalTrials.gov record NCT03900026, source copy `cardio:ctgov-nct03900026-2025-08-29`, retrieved 2026-10-31)
- Completion: 2025-01-30 (actual) (ClinicalTrials.gov record NCT03900026, source copy `cardio:ctgov-nct03900026-2025-08-29`, retrieved 2026-10-31)
- Countries: United States; Australia; Canada; Hungary (ClinicalTrials.gov record NCT03900026, source copy `cardio:ctgov-nct03900026-2025-08-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03900026-2025-08-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery
- Acronym: NEWTON-CABG
- Condition: Coronary Artery Bypass Graft Surgery
- Condition: Atherosclerosis
- Condition: Vein Occlusion
- Intervention (Drug): Evolocumab
- Intervention (Other): Placebo
- Lead sponsor: Unity Health Toronto
- Lead sponsor class: OTHER
- Collaborator: Applied Health Research Centre
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Unity Health Toronto (`cardio:org-unity-health-toronto`)
- Registry lists this organization as a collaborator: Applied Health Research Centre (`cardio:org-applied-health-research-centre`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial (`cardio:pubmed-40907505`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: fea01e46208819a5bf1d4e4bd079dfe9fe47c7b307a440e411ea2a357d15823c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
